Industry Recognition Honors Visionary Leader in Pharmaceutical Digital Transformation
On April 12, the 2026 Wuzhen Health Conference—the premier annual gathering of China’s pharmaceutical and health industry—announced the recipients of the prestigious West Lake Award for Outstanding Figures in China’s Pharmaceutical Industry. Among the honorees was Ms. Yi Wang, Founder and Chairperson of Chongqing Wei Yikang Pharmaceutical Technology Co., Ltd. and Qian Cheng (Chongqing) Pharmaceutical Co., Ltd., recognized for her more than two decades of sustained leadership, strategic innovation, and transformative contributions to pharmaceutical commerce and digital health ecosystem development.
With over 20 years of hands-on experience spanning sales operations, market strategy, channel management, and corporate leadership, Ms. Wang has evolved from a frontline pharmaceutical business executive into a nationally acknowledged industry architect. Her career includes senior leadership roles—including Regional Manager, Sales Director, and General Manager—at several leading domestic pharmaceutical enterprises, where she cultivated deep expertise in commercial execution, regulatory-compliant market expansion, and end-to-end supply chain optimization.
A recognized authority in pharmaceutical e-commerce, Ms. Wang brings 17 years of specialized operational insight to her current ventures. She serves as Dean of the Badianhui Mantianxing E-Commerce Academy and as a mentor in the “Four Beauties of Chinese Pharma” Future Star Program—an initiative supporting next-generation pharmaceutical leaders. Early in the industry’s digital pivot, she pioneered the “Omnichannel Full-Control, Ecosystem-Closed Loop” service model—a framework designed to integrate strategic consulting, platform-based e-commerce operations, cross-channel resource orchestration, and talent development into a unified, scalable solution for pharmaceutical enterprises.
Under her leadership, Wei Yikang and Qian Cheng have developed a comprehensive digital transformation platform tailored to the unique challenges faced by both legacy pharmaceutical manufacturers and emerging health brands. Their integrated offering includes brand positioning, product lifecycle strategy, omnichannel traffic acquisition, conversion optimization, pharmacovigilance-aligned compliance governance, and certified digital talent incubation. To date, the companies have partnered with more than 100 pharmaceutical organizations—enabling measurable growth in online prescription and OTC channel performance, improving regulatory adherence across digital touchpoints, and establishing new benchmarks for service excellence in pharmaceutical e-commerce.
The West Lake Award underscores not only Ms. Wang’s individual distinction as a clinician-informed strategist and digital health innovator but also affirms the growing impact of her organizations in advancing systemic modernization across China’s pharmaceutical value chain. As regulatory frameworks evolve—including recent NMPA guidance on internet-based drug sales and AI-augmented patient engagement—their evidence-informed, compliance-first approach positions them at the forefront of sustainable, scalable digital health commercialization.
Looking ahead, Ms. Wang and her teams remain committed to advancing high-quality development in China’s pharmaceutical industry through continuous R&D in health-tech integration, expanded training initiatives for pharmacy professionals in digital literacy, and deeper collaboration with academic institutions and regulatory stakeholders to shape best practices in ethical, patient-centered pharmaceutical commerce.